Intelligence Feed event · Policy · 2026-06-29

    Study Shows 16% of Patients Return to Humira After Biosimilar Switch

    Question

    Study Shows 16% of Patients Return to Humira After Biosimilar Switch

    Direct answer

    A large-scale study of 68,000 patients reveals that while biosimilar adoption is increasing, a significant portion of patients return to the original Humira product. This 're-switching' phenomenon suggests that the competitive threat from biosimilars may be less severe than initially feared by the market. This data supports AbbVie's (ABBV) recent stock performance, as it indicates a more durable revenue stream from its flagship product even after patent expiration.

    Original publisher
    Market Ontology
    Evidence through
    2026-06-29
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Study Shows 16% of Patients Return to Humira After Biosimilar Switch”, revision 1, evidence through 2026-06-29. https://marketontology.com/market-events/2026-06-29/study-shows-16-of-patients-return-to-humira-after-biosimilar-switch-a26cb8

    POLICY
    Study Shows 16% of Patients Return to Humira After Biosimilar Switch
    A large-scale study of 68,000 patients reveals that while biosimilar adoption is increasing, a significant portion of patients return to the original Humira product. This 're-switching' phenomenon suggests that the competitive threat from biosimilars may be less severe than initially feared by the market. This data supports AbbVie's (ABBV) recent stock performance, as it indicates a more durable revenue stream from its flagship product even after patent expiration.
    ABBV
    Impact
    70
    JUN 29
    SIG
    90%
    ABBV
    Study Shows 16% of Patients Return to Humira After Biosimilar Switch
    A large-scale study of 68,000 patients reveals that while biosimilar adoption is increasing, a significant portion of patients return to the original Humira product. This 're-switching' phenomenon suggests that the competitive threat from biosimilars may be less severe than initially feared by the market. This data supports AbbVie's (ABBV) recent stock performance, as it indicates a more durable revenue stream from its flagship product even after patent expiration.
    → Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue.
    Impact
    A large-scale study of 68,000 patients reveals that while biosimilar adoption is increasing, a significant portion of patients return to the original Humira product. This 're-switching' phenomenon suggests that the competitive threat from biosimilars may be less severe than initially feared by the market. This data supports AbbVie's (ABBV) recent stock performance, as it indicates a more durable revenue stream from its flagship product even after patent expiration.
    Affected
    ABBV
    Transmission
    Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month